Investor Handout Q3 2014

Size: px
Start display at page:

Download "Investor Handout Q3 2014"

Transcription

1 Investor Handout Q October 30, 2014

2 This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Figures for 2012 have been restated due to changes in accounting policies relating to the accounting standards IAS 19R ( Employee Benefits ) and IFRS 11 ( Joint Arrangements ). In addition, Bayer changed accounting for the stock-based compensation program. Disclaimer

3 The New Bayer Creating Value as an Innovation and Science Company HealthCare CropScience Human Health Animal Health Plant Health Build on a track record of success in science and innovation Address attractive markets with high growth rates and profitability Exit MaterialScience high-tech polymers by mid-2016 at the latest Page 1 Bayer Investor Handout October 30, 2014 The New Bayer A Pure Life Science Player Sales Split 2013 By Subgroup* Health Care Material Science HealthCare bn sales Pharmaceuticals 11.2bn, leading positions in core indications Consumer Health 7.7bn, OTC #2, blood glucose meters #3, Animal Health #5, contrast media #1 Crop Science CropScience - 8.8bn sales Chemical crop protection & biologicals #2, seeds & traits Page 2 Bayer Investor Handout October 30, 2014 *Excluding reconciliation

4 The New Bayer Setting Trends in Research-Intensive Areas of Life Science Page 3 Bayer Investor Handout October 30, 2014 Performance/ Aspirations

5 Q Strong Organic Growth / Earnings Performance Impacted By FX Sales in million % currency & portfolio adj. EBIT in million EBITDA adjusted* in million Core EPS in 9,643 10,187 1,221 1,376 1,984 2, Q3 13 Q3 14 Q3 13 Q3 14 Q3 13 Q3 14 Q3 13 Q % +13% +1% +6% Page 5 Bayer Investor Handout October 30, 2014 *before special items Q Full-Year Group Guidance Raised Sales Fx and portfolio adjusted, EBITDA before special items E as of Feb 14 (Avg. Fx rates Q4 13) 2014E* (Spot Fx rates as of Sep 30, 2014 for Q4 14) Sales 40.2bn ~5% to ~ 41-42bn (neg. FX effect approx. -2%) ~6% to ~ 42bn (neg. FX effect approx. -3%) adj. EBITDA 8.4bn low- to mid-singledigit % increase (neg. FX effect approx. -5%) mid-single-digit % increase (neg. FX effect approx. -5%) core EPS 5.61 mid-single-digit % increase (neg. FX effect approx. -6%) mid- to high-singledigit % increase (neg. FX effect approx. -7%) Page 6 Bayer Investor Handout October 30, 2014 Outlook depends on specific planning assumptions as detailed in the Annual Report *including Merck & Co. Consumer Care business from Oct 1, 2014

6 Aspirations for HealthCare and CropScience Division Sales CAGR ( ) EBITDA margin 2016 (before special items) HealthCare 6% ~30% Pharma 8% 33% Consumer Health* 3% ~24% CropScience 6% 24-25% Consumer Health aspirations will be updated to include Merck & Co. Consumer Care and Dihon Pharmaceutical Group after publication of Q4 results Page 7 Bayer Investor Handout October 30, 2014 *Excluding pending transactions Deliver Profitable Growth

7 One of the Fastest-Growing Global Pharma Companies Pharma Sales billion; % Fx & portfolio adj. +1% % +4% % M 2014 Plans for continued growth Maximize the value of launch products Drive commercial excellence in marketing and sales Advance early and mid-stage pipeline Achieve Phase III readiness for 5 projects in 2015 Explore opportunities for partnerships, open innovation and bolt-on acquisitions Page 9 Bayer Investor Handout October 30, 2014 Pharma Launch Products Drive Growth - Combined Peak Sales Potential of 7.5bn Collective Sales billion 9M 2014 Individual Sales million ~ ,163 Total 2,1bn e Page 10 Bayer Investor Handout October 30, 2014

8 Aspiring for OTC Leadership Consumer Care Sales billion, 2013 pro forma Merck & Co. Consumer Care; pending Achievements Strong #2 position Some of the world s most recognized brands Track record of outperforming market growth Success in long-term brand building Highly complementary acquisitions, incl. Merck OTC Plans for continued growth Globalize established brands Launch innovation pipeline Execute Emerging Markets focus strategies Fully realize synergy potential from acquisitions Target strategic acquisitions and alliances Page 11 Bayer Investor Handout October 30, 2014 Aspiring for Crop Protection Leadership CropScience Sales billion; % Fx & portfolio adj. +9% +12% +9% % M 2014 Plans for continued growth Strengthen portfolio through focused and integrated crop solutions Drive commercial excellence in marketing and sales Drive new product growth, invest in life-cycle management Extend seeds portfolio by building business in soybeans and wheat Page 12 Bayer Investor Handout October 30, 2014

9 New Products Drive Growth at Crop Protection Sales of New Crop Protection Products by Segment (2013) billion; new products launched since 2006; % y-o-y, fx adj. 2.6 Insecticides Fungicides +33% bn Herbicides Seed Growth e 2016e New products generated 82% of absolute sales growth at Crop Protection Page 13 Bayer Investor Handout October 30, 2014 Develop New Growth Opportunities

10 High Confidence in R&D Investments R&D Budget 2014 billion Pharma Consumer Health 0.9 Crop Science Achievements 25 successful Phase III clinical trials at Pharma since 2010 Strengthened brands through multiple line or product introductions in Consumer Care Launched 30 active ingredients between 2000 and 2013 in CropScience Initiated R&D projects that leverage synergies between human, animal and plant health Expect R&D-to-sales ratio to increase Page 15 Bayer Investor Handout October 30, 2014 Track Record - 25 Successful Phase III Clinical Trials at Pharma Since 2010 Major examples Various indications incl. treatment of deep vein thrombosis/pulmonary embolism, stroke prevention in atrial fibrillation and secondary prevention of acute coronary syndrome Wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization and central retinal vein occlusion Metastatic colorectal cancer and metastatic gastrointestinal stromal tumors Metastatic castration-resistant prostate cancer with symptomatic bone metastases Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Radioactive iodine refractory differentiated thyroid cancer Damoctocog alfa pegol Long-acting rfviii Prophylaxis in hemophilia A: Site-specific PEGylated Factor VIII with potential for 5-/ 7-days dosing intervals Page 16 Bayer Investor Handout October 30, 2014

11 Mid- and Late-Stage Pharma Pipeline Progressing Project Mechanism Indication Status Copanlisib (BAY ) PI3-Kinase Inhibitor Cancer Phase II in NHL ongoing Finerenone (BAY ) MR Antagonist Chronic heart failure (CHF) Diabetic nephropathy (DN) Phase IIb in CHF ongoing; phase II in DN completed Molidustat (BAY ) HIF-PH Inhibitor Anemia Phase IIb ongoing Vericiguat (BAY ) Vilaprisan (sprm) (BAY ) sgc Stimulator Progesterone Receptor Antagonist Worsening chronic heart failure Symptomatic uterine fibroids Phase IIb ongoing; collaboration with Merck & Co. Inc. Phase IIb ongoing ODM-201 AR Antagonist Non-metastatic castrationresistant prostate cancer Phase III ongoing Page 17 Bayer Investor Handout October 30, 2014 MR: Mineralocorticoid receptor; NHL: Non-Hodkin s lymphoma HIF-PH: HIF prolyl hydroxylase; sgc: Soluble guanylate cyclase; sprm: Selective progesterone receptor modulator; AR: Androgen receptor Regorafenib Eye Drops Could Become a Significant Advance in Treating wamd Current standard: intravitreal injection Injection into the eye Project goal: topical (drops) Eye drops Regorafenib inhibits VEGF* receptor signaling, a well-established principle to treat wamd** Regorafenib eye drops may allow topical treatment of wamd Targeting non-inferior efficacy but reduced efforts, costs and logistics as well as greater convenience Phase IIa/b initiated (completion expected early 2016) Page 18 Bayer Investor Handout October 30, 2014 *Vascular endothelial growth factor **Wet age-related macular degeneration

12 Copanlisib Potential New Treatment for Patients with Non-Hodgkin s Lymphoma 18 FDG-PET scans of a follicular lymphoma patient with partial response PI3k inhibitor targeting liquid tumors Phase II in non-hodgkin s lymphoma ongoing - preliminary results* encouraging: Significant activity shown Complete responses observed in several forms of NHL** Phase II completion expected 1H year-old female with FL, grade 1-2, diagnosed stage IVa Given positive trial results, a successful development program overall and regulatory approval, best-case scenario could see first launch as early as 2016 Page 19 Bayer Investor Handout October 30, 2014 *Dreyling et al. ASH 2013; **in FL, mantle cell lymphoma, peripheral T-cell lymphoma and diffuse large B-cell lymphoma Expect Significant Newsflow from Progressing Pharma Pipeline Asset Intended Indication Status/ Expected Completion Milestone / Data Presentation* Targeted Finerenone Mineralocorticoid receptor antagonist Diabetic nephropathy Phase IIb; compl. 2H 2014e WCN March 2015e Wors. chronic heart failure Phase IIb; compl. end 2014e ESC Aug/Sept 2015e Vilaprisan Progesterone receptor antagonist Uterine fibroids Phase IIb; completion end 2015e Phase IIa data at SRI March 2015e Vericiguat sgc stimulator Wors. chronic heart failure Phase IIb; reduced ejection fraction - compl. mid 2015e Phase IIb; preserved ejection fraction - compl. mid 2015e AHA Nov 2015e Damoctocog alfa pegol Long-acting FVIII Copanlisib PI3 kinase inhibitor Regorafenib Multikinase inhibitor Molidustat HIF-PH inhibitor Hemophilia A Data from Phase III reported Filing mid 2016e Non-Hodgkin s lymphoma Phase II completion 1H 2015e ASH Dec 2015e Wet AMD (eye drops) Phase II completion 1H 2016e tbd Anemia Phase II completion 2H 2015e tbd ODM-201 Androgen receptor antagonist Non-metastatic castrationresistant prostate cancer Phase III completion 2018e tbd Page 20 Bayer Investor Handout October 30, 2014 *Current plan for presentation

13 Continuous Flow of Product Innovation with Promising Potential at CropScience Innovation Execution Potential Chemicals Biologicals Seeds&Traits LCM Products launched * Peak sales 4bn 8 Chemicals 2 Herbicides 2 Fungicides 2 Insecticides 2 SeedGrowth 2 Biologicals 1 Fungicide 1 Insecticide 15 Seeds/traits 3 Cotton 6 Oilseed 4 Rice 1 Soybean 1 Wheat Seed varieties Several hundred new varieties in vegetables and broad acre crops Life-cycle management New formulations and mixtures, incl. Biologicals Page 21 Bayer Investor Handout October 30, 2014 *Estimated and subject to regulatory approval Sivanto A New Premium Insecticide for Fruit and Vegetable Growers Significant benefits to growers quick feeding cessation effective virus vector control flexible applicability at any crop stage higher-quality produce at harvest Outstanding safety profile Use in fruits, vegetables and selected broad-acre crops Resistance management by novel butenolide chemistry (flupyradifurone) First launch in 2015* Page 22 Bayer Investor Handout October 30, 2014 *Planned first registrations for foliar application; SeedGrowth use planned to follow subsequently

14 Life-Cycle Management Generates Returns Beyond Patent Expiry Sales Example: Fungicide Trifloxystrobin Nativo brand family Other brands Patent expiry Key Activities Innovative mixtures with IP Examples: Fox, Stratego Yield Efficiency gains by production process optimization Explore product properties beyond efficacy Examples: yield, quality, abiotic stress Develop integrated crop solutions Example: Much More Rice Page 23 Bayer Investor Handout October 30, 2014 Building a Global Wheat Seed Business Largest Broad-Acre Crop Worldwide Measures Taken 7 wheat breeding centers operating Acquisition of superior germplasm Numerous alliances Significant R&D investments Planned Market Entry Launch of first variety planned in 2015 Suitable for Ukraine Open pollinated variety Hybrid seed varieties, providing opportunity for both yield increase and improved yield stability, expected after 2020 Market value still small - major potential seen with productivity improvement Page 24 Bayer Investor Handout October 30, 2014

15 The Life Science Approach Promises Opportunities What we have achieved What we aim to achieve World-class Life Science businesses R&D excellence in established areas Track record of success in bringing innovation to patients and farmers Maintain R&D productivity and innovation leadership in existing areas and establish leading positions in new areas Gain new perspectives and explore the Life Science approach to target breakthrough innovations that address unmet needs Page 25 Bayer Investor Handout October 30, 2014 Similar Challenges within Human, Animal and Plant Health Can Stimulate Life Science R&D Related challenges for human, animal and plant health* Potential for collaboration & synergies Regain control over unregulated growth Bring upcoming resistances back under control Understand and exploit the hostmicrobe interaction Page 26 Bayer Investor Handout October 30, 2014 *Examples

16 Transforming into a Pure Life Science Company Portfolio Evolution Transaction Volume > 47bn Since 2004* Major examples only 2003 Sales 28.6bn Pro-Forma 2013 Sales 29.3bn HealthCare CropScience Diagnostics Plasma Divestitures 11bn Merck & Co. Consumer Care Dihon** Algeta Conceptus Steigerwald GmbH Teva Animal Health Schering AG Roche OTC HealthCare MaterialScience Capital-market exit planned Acquisitions 36bn Chemicals HC Starck Wolff Walsrode Lanxess spin-off Bayer Silicones Divested Divested AgraQuest + Athenix + Stoneville Cotton Seed + Gustafson Seed Treatment + CropScience Headcount: 115,400 Pro-forma headcount: 99,000 Page 28 Bayer Investor Handout October 30, 2014 *Transaction volume: acquisitions/divestments Aug 2014 **Closing expected in H2 2014

17 2014 Acquisitions Significantly Strengthen HealthCare Portfolio Algeta: Oncology portfolio Full control over Xofigo Comprehensive life-cycle management: studies in earlier settings of prostate cancer, combination studies, and other tumors Merck Consumer Care: American OTC/CC brands Creating global OTC #2 Scaling-up US business to #1 Gaining global leadership in dermatology and GI Entry into new categories: allergy, suncare, footcare Dihon Pharmaceutical Group: Chinese OTC brands Creating leading position amongst multinationals in OTC in China Access to lower-tier cities Page 29 Bayer Investor Handout October 30, 2014 Note: Algeta closed in Mar 2014; Dihon signed in Feb 2014; Merck & Co. Consumer Care signed in May 2014 Demerger of MaterialScience: Leverage the Competitive Edge Strong fundamentals for successful operations Leading #1 & #2 positions in attractive, growing markets Broad customer base Global production network providing customer proximity State-of-the art process technology Significant investments in new plants during recent years... better leveraged as a separate company Ability to further develop own portfolio Autonomous funding capability Opportunity to develop a culture fitting with the business Tailored business processes and incentive systems MaterialScience has the potential to deliver significant value creation as a stand-alone business Page 30 Bayer Investor Handout October 30, 2014

18 Demerger of MaterialScience: Design of Planned Capital-Market Exit H H /18 Supervisory Board Decision - Exit MaterialScience Preparation of pro-forma financials Design of MaterialScience New Legal carve-out Expected first trading day of MaterialScience New shares Targeted time frame for capital-market exit: months Timing and structure of capital-market exit option depending on future market environment Investment of any potential proceeds mainly in Life Science businesses/ reduction of net debt Unhindered business operations safeguarded during exit preparation Page 31 Bayer Investor Handout October 30, 2014 Summary

19 The New Bayer - A World-Class Life Science Company Leadership One of the fastest-growing global pharma companies On our way to OTC leadership Aspiring for Crop Protection leadership Capabilities Value Excellence in R&D and commercialization Leveraging leading brands with decade-long brand equity Superior emerging-market presence Progressing innovation pipeline Setting trends in research-intensive areas in the field of human, animal and plant health Leveraging sales growth into value creation Page 33 Bayer Investor Handout October 30, 2014

20

21 Date Event Publication Thursday, February 26, 2015 Thursday, April 30, 2015 Wednesday, May 27, 2015 Wednesday, July 29, 2015 Thursday, October 29, 2015 Investor Conference Call Investor Conference Call Annual General Meeting Investor Conference Call Investor Conference Call 2014 Annual Report First Quarter 2015 Results Stockholders Newsletter Second Quarter 2015 Results Stockholders Newsletter Third Quarter 2015 Results Stockholders Newsletter Reporting Events and AGM

22 Dr. Alexander Rosar Head of Investor Relations Phone: Dr. Jürgen Beunink Phone: Judith Nestmann Phone: Peter Dahlhoff Phone: Constance Spitzer Phone: Dr. Olaf Weber Phone: Investor Relations Contacts

The New Bayer. London, September 30, 2014 / Marijn Dekkers, CEO

The New Bayer. London, September 30, 2014 / Marijn Dekkers, CEO The New Bayer Creating Value as an Innovation and Science Company London, September 30, 2014 / Marijn Dekkers, CEO Page 1 Meet Management Marijn Dekkers September 30, 2014 Disclaimer This presentation

More information

Investor Handout Q3 2014

Investor Handout Q3 2014 Investor Handout Q3 2014 November 2014 This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and

More information

Investor Handout. Berenberg European Conference. Kemal Malik, Member of the Board of Management of Bayer AG

Investor Handout. Berenberg European Conference. Kemal Malik, Member of the Board of Management of Bayer AG Investor Handout Berenberg European Conference Kemal Malik, Member of the Board of Management of Bayer AG December 03, 2014 This presentation may contain forward-looking statements based on current assumptions

More information

Investor Handout June 2015

Investor Handout June 2015 Investor Handout June 2015 This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks,

More information

London, November Liam Condon, CEO of Bayer CropScience

London, November Liam Condon, CEO of Bayer CropScience DRAFT0 UBS European Conference London, November 2014 Liam Condon, CEO of Bayer CropScience Page 1 Bayer Investor Presentation CropScience November 2014 Disclaimer This presentation may contain forward-looking

More information

Move to significantly strengthen position in consumer care

Move to significantly strengthen position in consumer care Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Move to significantly strengthen position in consumer care Bayer to acquire consumer care business of US-based

More information

Investor Handout. March 2017

Investor Handout. March 2017 Investor Handout March 2017 Cautionary Statements Regarding Forward- Looking Information Certain statements contained in this communication may constitute forward-looking statements. Actual results could

More information

Acquisition of Monsanto to Create a Global Leader in Agriculture

Acquisition of Monsanto to Create a Global Leader in Agriculture Acquisition of Monsanto to Create a Global Leader in Agriculture Innovation Powerhouse to Deliver Integrated Solutions for the Next Generation of Farming dbaccess German, Swiss & Austrian Conference June

More information

Bayer: improving people s lives through innovation

Bayer: improving people s lives through innovation Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Perspective on Innovation 2012: Bayer: improving people s lives through innovation Some EUR 3 billion for research

More information

Science For A Better Life

Science For A Better Life Science For A Better Life Innovation, performance and commitments Defining our priorities Dr. Marijn Dekkers UBS Global Life Science Conference September 22, 2010 Science For A Better Life This presentation

More information

Wenning: We have great confidence for the future

Wenning: We have great confidence for the future Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Investor conference in London on research and development: Wenning: We have great confidence for the future Phase

More information

Science For A Better Life. Morgan Stanley Consumer Health Symposium. Gary Balkema President, Consumer Care Bayer HealthCare

Science For A Better Life. Morgan Stanley Consumer Health Symposium. Gary Balkema President, Consumer Care Bayer HealthCare Science For A Better Life Morgan Stanley Consumer Health Symposium Gary Balkema President, Consumer Care Bayer HealthCare January 25 2008 Important Information This presentation may contain forward-looking

More information

CSFB Chemical Hybrid Tour

CSFB Chemical Hybrid Tour CSFB Chemical Hybrid Tour September 21, 2005 Bayer CropScience Creating Value through Innovation Dr. Bernward Garthoff Member of the Board of Management Bayer CropScience Safe Harbor This presentation

More information

BASF signs agreement to acquire significant parts of Bayer s seed and non-selective herbicide businesses. October 13, 2017

BASF signs agreement to acquire significant parts of Bayer s seed and non-selective herbicide businesses. October 13, 2017 BASF signs agreement to acquire significant parts of Bayer s seed and non-selective herbicide businesses October 13, 2017 Cautionary note regarding forward-looking statements This presentation contains

More information

Bayer 2022: Delivering Value Creation

Bayer 2022: Delivering Value Creation Bayer 2022: Delivering Value Creation /////////// Roadshow Singapore & Australia January 5 th - 7 th, 209 Werner Baumann CEO Bayer AG 208: Progress Across all Divisions Delivering on Guidance Despite Headwinds

More information

Investor News. Bayer plans further expansion in Asia. Perspective on Growth in Asia

Investor News. Bayer plans further expansion in Asia. Perspective on Growth in Asia Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Perspective on Growth in Asia Bayer plans further expansion in Asia Sales in the region to grow to well over EUR

More information

Bayer CropScience plans to further expand business with high-margin products and new crops

Bayer CropScience plans to further expand business with high-margin products and new crops Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Solutions from sowing to the harvest: Bayer CropScience plans to further expand business with high-margin products

More information

Bayer R&D Investor Day 2005

Bayer R&D Investor Day 2005 Science For A Better Life HealthCare Bayer R&D Investor Day 2005 December 8, 2005 London Bayer R&D Investor Day 2005 Bayer HealthCare R&D Arthur J. Higgins Chairman of the Executive Board Bayer HealthCare

More information

Forward Looking Statements. Dr. Jochen Wulff Chief Executive Officer Bayer CropScience

Forward Looking Statements. Dr. Jochen Wulff Chief Executive Officer Bayer CropScience Dr. Jochen Wulff Chief Executive Officer Bayer Crop Forward Looking Statements This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Crop AG management.

More information

THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT BAYN.DE - Bayer AG Meet Management in Leverkusen EVENT DATE/TIME: MARCH 12, 2014 / 08:00AM GMT

THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT BAYN.DE - Bayer AG Meet Management in Leverkusen EVENT DATE/TIME: MARCH 12, 2014 / 08:00AM GMT THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT BAYN.DE - Bayer AG Meet Management in Leverkusen EVENT DATE/TIME: MARCH 12, 2014 / 08:00AM GMT 1 CORPORATE PARTICIPANTS Alexander Rosar Bayer AG Leverkusen

More information

Lehman Brothers Global Chemical Industry Leaders Conference. March 18, Dr. Rüdiger Scheitza. Member of the Board of Mangement Bayer CropScience

Lehman Brothers Global Chemical Industry Leaders Conference. March 18, Dr. Rüdiger Scheitza. Member of the Board of Mangement Bayer CropScience Lehman Brothers Global Chemical Industry Leaders Conference March 18, 2005 Dr. Rüdiger Scheitza Member of the Board of Mangement Bayer CropScience Forward Looking Statements This presentation contains

More information

5. Research, Development, Innovation

5. Research, Development, Innovation Bayer Annual Report 2014 63 Growth of the global furniture industry improved in 2014 compared with the previous year, with the industry benefiting from the progressive market recovery in North America

More information

Investor Handout Q1 l 2010

Investor Handout Q1 l 2010 Investor Handout Q1 l 2010 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various

More information

AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update

AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. November 4, 2016 AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter

More information

Strategy Agricultural Products

Strategy Agricultural Products Strategy Agricultural Products Hans W. Reiners President Agricultural Products Division August 2005 1 Agricultural Products Strategy Delivers Results 2 Half-Year 2005 Performance 3 Setting the Benchmark

More information

The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2

The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2 News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes

More information

UPL + Arysta: Creating a global leader in agricultural solutions. July 2018

UPL + Arysta: Creating a global leader in agricultural solutions. July 2018 UPL + Arysta: Creating a global leader in agricultural solutions July 2018 Disclaimer This document contains certain forward-looking statements with respect to the financial condition, results of operations

More information

Building Bayer CropScience. Crop Protection

Building Bayer CropScience. Crop Protection Building Bayer CropScience Disclaimer Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various

More information

Bayer Investor Handout Deutsche Bank Access Asia Conference

Bayer Investor Handout Deutsche Bank Access Asia Conference Bayer Investor Handout Deutsche Bank Access Asia Conference Singapore, May 2017 Cautionary Statements Regarding Forward-Looking Information Certain statements contained in this communication may constitute

More information

INVESTOR HANDOUT Meet Management

INVESTOR HANDOUT Meet Management INVESTOR HANDOUT Meet Management March 15, 2017 London Cautionary Statements Regarding Forward-Looking Information Certain statements contained in this communication may constitute forward-looking statements.

More information

Company Profile. German-Taiwan Biotech Seminar 6 November 2017

Company Profile. German-Taiwan Biotech Seminar 6 November 2017 Company Profile German-Taiwan Biotech Seminar 6 November 2017 Our Mission Bayer: Science For A Better Life A growing and aging world population requires an adequate supply of food and improved medical

More information

Chief Executive Officer s speech

Chief Executive Officer s speech April 29, 2014, Basel, Switzerland Annual General Meeting Syngenta AG Chief Executive Officer s speech Mike Mack, CEO Good morning. The last three years have been a time of intense activity at our company.

More information

Financial News Conference

Financial News Conference Financial News Conference Leverkusen, February 22, 2017 Werner Baumann, CEO of Bayer AG Bayer Again Very Successful Operationally and Strategically New record for operating performance Agreed acquisition

More information

Bayer s Contribution to a Healthier Society

Bayer s Contribution to a Healthier Society Bayer s Contribution to a Healthier Society 12th Japan-Germany Industry Forum in Tokyo Dec. 1 st, 2016 / Hans-Dieter Hausner, President and Senior Bayer Representative at Bayer Holding Ltd. Our Mission

More information

2013 Half Year Results

2013 Half Year Results 2013 Half Year Results Basel: July 24, 2013 Safe harbor This document contains forward-looking statements, which can be identified by terminology such as expect, would, will, potential, plans, prospects,

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group Roadshow Benelux June 29/30, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

More information

CORPORATE PRESENTATION January 2019

CORPORATE PRESENTATION January 2019 CORPORATE PRESENTATION January 2019 1 DISCLAIMER This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ( Outlook Therapeutics or the Company ) based on management s current

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group Roadshow Copenhagen October 6, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

More information

1 Introduction 2 BASF Crop Protection 3 BASF Plant Biotechnology Dr. Peter Eckes President, BASF Plant Science

1 Introduction 2 BASF Crop Protection 3 BASF Plant Biotechnology Dr. Peter Eckes President, BASF Plant Science 1 1 Introduction 2 BASF Crop Protection 3 BASF Plant Biotechnology Dr. Peter Eckes President, BASF Plant Science The GM success story continues Global GM crop area in million hectares; 1 ha = 2.47 acres

More information

Macquarie 12 th Annual Australian Conference

Macquarie 12 th Annual Australian Conference Macquarie 12 th Annual Australian Conference Sydney Doug Rathbone Chief Executive Officer May, 2011 The broader picture. Agriculture remains a strong growth industry Declining stock-to-use ratios Rising

More information

Bank of America Merrill Lynch Healthcare Conference. September 13, 2013

Bank of America Merrill Lynch Healthcare Conference. September 13, 2013 Bank of America Merrill Lynch Healthcare Conference September 13, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and

More information

Science For A Better Life

Science For A Better Life Science For A Better Life Credit Suisse 14th Annual Global Ag Productivity Conference Dr. Rüdiger Scheitza Member of the Board of Management of Bayer CropScience AG March 11 2009 London Important Information

More information

Regeneron Reports Third Quarter 2010 Financial Results and Business Highlights

Regeneron Reports Third Quarter 2010 Financial Results and Business Highlights Regeneron Reports Third Quarter 2010 Financial Results and Business Highlights TARRYTOWN, N.Y., Oct 28, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today

More information

Bayer CEO Wenning at the inauguration of new production facilities in Shanghai

Bayer CEO Wenning at the inauguration of new production facilities in Shanghai Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer CEO Wenning at the inauguration of new production facilities in Shanghai China is of central importance to

More information

Health Care Worldwide. Crédit Suisse Global Credit Products Conference October 1, Barcelona

Health Care Worldwide. Crédit Suisse Global Credit Products Conference October 1, Barcelona Health Care Worldwide Crédit Suisse Global Credit Products Conference October 1, 2015 - Barcelona Safe Harbor Statement This presentation contains forward-looking statements that are subject to various

More information

Shaping agriculture in changing times Markus Heldt, President BASF Crop Protection. Global Press Conference BASF Crop Protection September 6, 2016

Shaping agriculture in changing times Markus Heldt, President BASF Crop Protection. Global Press Conference BASF Crop Protection September 6, 2016 Shaping agriculture in changing times Markus Heldt, President BASF Crop Protection Global Press Conference BASF Crop Protection September 6, 2016 Ongoing contribution and commitment to agriculture AgCelence

More information

CONFERENCE CALL 2015 RESULTS. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY

CONFERENCE CALL 2015 RESULTS. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY CONFERENCE CALL 205 RESULTS Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains forward-looking statements that

More information

First Quarter 2018 Financial Results. May 8, 2018

First Quarter 2018 Financial Results. May 8, 2018 First Quarter 2018 Financial Results May 8, 2018 Agenda Introduction Sarah Carmody, Senior Director of Investor Relations Corporate Update Craig Wheeler, President and Chief Executive Officer First Quarter

More information

Forward Looking Statements. Spring Investor Conference Bayer Group March 19, 2004

Forward Looking Statements. Spring Investor Conference Bayer Group March 19, 2004 Spring Investor Conference Bayer Group March 19, 2004 Jochen Wulff Chief Executive Officer (CEO) Bayer CropScience Forward Looking Statements This presentation contains forward-looking statements based

More information

CEO Werner Wenning at the Annual Stockholders Meeting of Bayer AG:

CEO Werner Wenning at the Annual Stockholders Meeting of Bayer AG: News Release Bayer AG Communications 51368 Leverkusen Germany Tel. +49 214 30-1 www.press.bayer.com CEO Werner Wenning at the Annual Stockholders Meeting of Bayer AG: We plan to grow again 2009 operationally

More information

Your partner for growth

Your partner for growth Your partner for growth A New Market Leader Takes Shape Goldman Sachs Annual Ag Forum February 27th, 2003 Dr. Esmail Zirakparvar Member of the Board of Management Bayer CropScience AG Disclaimer: Forward-Looking

More information

Arcadia Biosciences. NobleConXV January 2019

Arcadia Biosciences. NobleConXV January 2019 Arcadia Biosciences NobleConXV January 2019 Forward-looking statements Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements

More information

Group to take comprehensive range of portfolio, efficiency and structural measures

Group to take comprehensive range of portfolio, efficiency and structural measures News Release Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-1 media.bayer.com Group to take comprehensive range of portfolio, efficiency and structural measures Bayer

More information

Simply. Grow. Together

Simply. Grow. Together Simply. Grow. Together Legal notice This presentation is for marketing and information purposes only. By this presentation, the ADAMA Group does not intend to give, and the presentation does not constitute,

More information

Globalization and Innovation will drive growth

Globalization and Innovation will drive growth JPMorgan Healthcare Conference The New Takeda January 10, 2012 Yasuchika Hasegawa President & CEO 0 Globalization and will drive growth Leading worldwide pharmaceutical company operating in 70 countries

More information

Company Presentation. September Frankfurt stock exchange: FRE US ADR program: FSNUY

Company Presentation. September Frankfurt stock exchange: FRE US ADR program: FSNUY Company Presentation September 2018 Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors Safe Harbor Statement This presentation contains forward-looking statements that are

More information

Rodman & Renshaw 20 th Annual Global Investment Conference. September 5, 2018

Rodman & Renshaw 20 th Annual Global Investment Conference. September 5, 2018 Rodman & Renshaw 20 th Annual Global Investment Conference September 5, 2018 Forward-looking statements Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: This presentation

More information

Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q

Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements

More information

JP Morgan Healthcare Conference Stefan Oschmann Head of Pharma. San Francisco, January 9, 2012

JP Morgan Healthcare Conference Stefan Oschmann Head of Pharma. San Francisco, January 9, 2012 JP Morgan Healthcare Conference Stefan Oschmann Head of Pharma San Francisco, January 9, 2012 Disclaimer Remarks All comparative figures relate to the corresponding last year s period. From 2007 the Generics

More information

Cryoport, Inc. Calendar Year 2017 Third Quarter Earnings Call NASDAQ: CYRX

Cryoport, Inc. Calendar Year 2017 Third Quarter Earnings Call NASDAQ: CYRX Cryoport, Inc. Calendar Year 2017 Third Quarter Earnings Call 1 Safe Harbor Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties.

More information

Delivering Value Creation

Delivering Value Creation Delivering Value Creation /////////// Capital Markets Day London, December 5, 2018 Werner Baumann CEO Bayer AG Disclaimer Cautionary Statements Regarding Forward-Looking Information This presentation contains

More information

Datamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar

Datamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease

More information

JP Morgan Global Healthcare Conference

JP Morgan Global Healthcare Conference JP Morgan Global Healthcare Conference January 12, 2016 Robert Friel, Chairman and CEO Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking" statements

More information

Universal Biosensors, Inc.

Universal Biosensors, Inc. Universal Biosensors, Inc. ARBN 121 559 993 UBS Global Life Sciences Conference New York September 2011 1 Important Disclaimer This presentation is intended to provide a general outline only and is not

More information

BASF Agricultural Solutions

BASF Agricultural Solutions BASF Agricultural Solutions Markus Heldt President Crop Protection Division Sanford Bernstein Annual Agriculture Conference London March 10, 2015 1 Positioning & strategy 2 Financial results & targets

More information

2009 Full Year Results. September, 2009

2009 Full Year Results. September, 2009 2009 Full Year Results September, 2009 Doug Rathbone Managing Director 2009 Full Year results A challenging year Glyphosate profit impact was substantial Credit related pressures in Brazil Non-glyphosate

More information

Bayer AG Corporate Responsibility. Ursula Mathar Bayer AG, Environment & Sustainability FAIRE 2007, June 11, Paris

Bayer AG Corporate Responsibility. Ursula Mathar Bayer AG, Environment & Sustainability FAIRE 2007, June 11, Paris Bayer AG Corporate Responsibility Ursula Mathar Bayer AG, Environment & Sustainability FAIRE 2007, June 11, Paris Disclaimer This presentation contains forward-looking statements based on current assumptions

More information

Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems

Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems Karin Mateu Media Relations Tel.: +41 (0) 58 286 44 09 karin.mateu@ch.ey.com Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems Glaxo is leading the way in

More information

31st Annual J.P. Morgan Healthcare Conference

31st Annual J.P. Morgan Healthcare Conference 31st Annual J.P. Morgan Healthcare Conference Achieving Sustainable Growth January 8, 2013 Yasuchika Hasegawa President & CEO 1 Forward-Looking Statements This presentation contains forward-looking statements

More information

Creating a Global Leader in Agriculture

Creating a Global Leader in Agriculture Creating a Global Leader in Agriculture Innovation Engine to Deliver Enhanced Solutions for the Next Generation of Farming Investor Conference Call September 14, 2016 Forward-Looking Statements Certain

More information

Bayer HealthCare Investor Day Growth Through Our Portfolio of Marketed Products (1)

Bayer HealthCare Investor Day Growth Through Our Portfolio of Marketed Products (1) Bayer HealthCare Investor Day 2007 Growth Through Our Portfolio of Marketed Products (1) Gunnar Riemann Business Units Oncology, Specialized Therapeutics, Cardiology/Hematology Member of the Board Bayer

More information

Health Care Worldwide. Bank of America, 2007 Health Care Conference, May 30, 2007

Health Care Worldwide. Bank of America, 2007 Health Care Conference, May 30, 2007 Health Care Worldwide Bank of America, 2007 Health Care Conference, May 30, 2007 1 Fresenius This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future

More information

Alliance for Japanese market - ips cell technology into practical use - Healios K.K. Dainippon Sumitomo Pharma, Co., Ltd.

Alliance for Japanese market - ips cell technology into practical use - Healios K.K. Dainippon Sumitomo Pharma, Co., Ltd. Alliance for Japanese market - ips cell technology into practical use - Healios K.K. Dainippon Sumitomo Pharma, Co., Ltd. December 2, 2013 Background March 28, 2013 Capital alliance: DSP took a 1.5billion

More information

Molecular Partners launches IPO on SIX Swiss Exchange

Molecular Partners launches IPO on SIX Swiss Exchange For release in Switzerland only. This is a restricted communication and you must not forward it or its contents to any person to whom forwarding it is prohibited by the legends contained therein. In particular,

More information

Welcome to Synchronoss 3.0

Welcome to Synchronoss 3.0 Welcome to Synchronoss 3.0 Intralinks Acquisition Overview and Activation Divestiture December 6, 2016 1 2016 Synchronoss, Inc. All Rights Reserved Safe Harbor. Forward-Looking Statements This presentation

More information

Full year results Amsterdam, 5 February 2015

Full year results Amsterdam, 5 February 2015 Full year results 2014 Amsterdam, 5 February 2015 Disclaimer The information contained herein shall not constitute or form any part of any offer or invitation to subscribe for, underwrite or otherwise

More information

Click to edit Master title style

Click to edit Master title style Growing Energy: Brazil and Beyond Click to edit Master title style Jefferies 2013 Global Industrials Conference Click to edit Master subtitle style Paul Kuc Chief Financial Officer August 12, 2013 Safe

More information

EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE

EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE , 09 MAY 2018 EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE 55% INCREASE IN GROUP REVENUES STRONG UNDERLYING OPERATIONAL PERFORMANCE WITH NEW BUSINESS MIX AFTER APTUIT ACQUISITION

More information

Building Bayer HealthCare & beyond. Investors Conference, Leverkusen March 15, 2002 Dr. Frank Morich

Building Bayer HealthCare & beyond. Investors Conference, Leverkusen March 15, 2002 Dr. Frank Morich Building Bayer HealthCare 2001 & beyond Investors Conference, Leverkusen March 15, 2002 Dr. Frank Morich The New Health Care 2001 Operating Performance EUR million Healthcare 10,821-1.9 943-42.3 Animal

More information

Commerzbank German Investment Seminar 2012

Commerzbank German Investment Seminar 2012 Commerzbank German Investment Seminar 2012 Matthias Zachert Chief Financial Officer New York, January 11, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck

More information

Roche: adapting to the changing environment. Severin Schwan, CEO Roche Group London, 15 September 2010

Roche: adapting to the changing environment. Severin Schwan, CEO Roche Group London, 15 September 2010 Roche: adapting to the changing environment Severin Schwan, CEO Roche Group London, 15 September 2010 This presentation contains certain forward-looking statements. These forward-looking statements may

More information

Cheuvreux German Corporate Conference 2012

Cheuvreux German Corporate Conference 2012 Cheuvreux German Corporate Conference 2012 Matthias Zachert Chief Financial Officer Frankfurt, January 17, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck

More information

Quarter End Results. Period Ended September 30, 2018

Quarter End Results. Period Ended September 30, 2018 Quarter End Results Period Ended September 30, 2018 Forward Looking Statement This presentation contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions

More information

For personal use only

For personal use only ANNUAL GENERAL MEETING MINTER ELLISON LEVEL 23, 525 COLLINS ST, MELBOURNE VIC 3000 AT 11.00 AM ON 26 NOVEMBER, 2014 CEO S ADDRESS Thank you Roger. Good morning Ladies and Gentlemen. It is a pleasure to

More information

SCP Workshop. Licensing & Health /////////// The real life / D. Immler

SCP Workshop. Licensing & Health /////////// The real life / D. Immler SCP Workshop Licensing & Health /////////// The real life 2018-12-04 / D. Immler Bayer is proud of its long-standing commitment to R&D Continuous Investment in R&D Projects Input Output Other 55 million

More information

Baxalta Incorporated. Third Quarter 2015 Financial Results Prepared Remarks

Baxalta Incorporated. Third Quarter 2015 Financial Results Prepared Remarks Baxalta Incorporated Third Quarter 2015 Financial Results Prepared Remarks Introduction: Mary Kay Ladone Good morning and welcome to the third quarter 2015 earnings conference call for Baxalta Incorporated.

More information

A Next Generation Stem Cell Therapeutics Company. Investor Presentation: Cynata Therapeutics Limited

A Next Generation Stem Cell Therapeutics Company. Investor Presentation: Cynata Therapeutics Limited A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited Important Information This presentation has been prepared by Cynata Therapeutics Limited. ( Cynata or

More information

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update August 2, 2013 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update Kadcyla sales off to strong start. Decision

More information

Strategic Collaboration with Amgen to develop MP0310

Strategic Collaboration with Amgen to develop MP0310 Strategic Collaboration with Amgen to develop MP0310 Patrick Amstutz, CEO Webcast of Molecular Partners AG, Switzerland (SIX: MOLN) December 19, 2018 2018 Molecular Partners AG Slide 1 Molecular Partners:

More information

CL King Best Ideas Conference

CL King Best Ideas Conference Leadership in Surface Modification and Drug Delivery Phil Ankeny, Senior Vice President and CFO CL King Best Ideas Conference The Omni Berkshire Place Hotel September 19, 2007 Safe Harbor Statement Some

More information

J.P. MORGAN Healthcare Conference Robert Friel Chairman and CEO January 10, 2018

J.P. MORGAN Healthcare Conference Robert Friel Chairman and CEO January 10, 2018 J.P. MORGAN Healthcare Conference Robert Friel Chairman and CEO January 10, 2018 Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking" statements

More information

BMO Capital Markets 10th Annual Farm to Market Conference BRETT BEGEMANN. President and Chief Operating Officer. May 20, 2015

BMO Capital Markets 10th Annual Farm to Market Conference BRETT BEGEMANN. President and Chief Operating Officer. May 20, 2015 BMO Capital Markets 10th Annual Farm to Market Conference BRETT BEGEMANN President and Chief Operating Officer May 20, 2015 Forward-Looking Statements Cautionary Statements Regarding Forward-Looking Information:

More information

Bringing a successful partnership to the next level

Bringing a successful partnership to the next level Bringing a successful partnership to the next level Basle, 21 July 2008 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as

More information

Bayer acquires new fungicide from Novartis

Bayer acquires new fungicide from Novartis Corporate Investor Relations Bayer acquires new fungicide from Novartis FLINT product line has blockbuster potential / Annual sales expected to reach EUR 300 million Leverkusen Bayer aims to achieve a

More information

Company Report Daring to be different

Company Report Daring to be different Company Report 2010 Daring to be different Daring to be different Galapagos has continued to follow its own unique path and is now a leading international biotechnology company. In our 2010 report, we

More information

The Future of Consumer Health Care

The Future of Consumer Health Care The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry 2 Creating a New Business Model in Consumer Health Care 3 Serve More Consumers In More Parts of the World, More

More information

INVESTOR PRESENTATION. January 2019

INVESTOR PRESENTATION. January 2019 INVESTOR PRESENTATION January 2019 IMPORTANT LEGAL NOTES ICL- AT A GLANCE $5.4B 49 ~11,000 TOP 3 $7.2B

More information

Biopharmaceuticals Investor & Analyst Day

Biopharmaceuticals Investor & Analyst Day Adequate picture Biopharmaceuticals Investor & Analyst Day Strategic perspective on Merck KGaA, Darmstadt, Germany Karl-Ludwig Kley CEO Darmstadt, Germany September 18, 2014 Disclaimer Remarks All comparative

More information

New Medium-term Management Plan Co-Creation April, 2017 March, 2022 Create innovative Drugs, Value, and Future with all efforts

New Medium-term Management Plan Co-Creation April, 2017 March, 2022 Create innovative Drugs, Value, and Future with all efforts New Medium-term Management Plan Co-Creation April, 2017 March, 2022 Create innovative Drugs, Value, and Future with all efforts Medium-term Management Plan: Co-Creation Five-year plan aiming for a stable

More information

Nestlé: strong foundation, clear path forward, bright future Mark Schneider: Chief Executive Officer. September 26, 2017 Nestlé Investor Seminar 2017

Nestlé: strong foundation, clear path forward, bright future Mark Schneider: Chief Executive Officer. September 26, 2017 Nestlé Investor Seminar 2017 Nestlé: strong foundation, clear path forward, bright future Mark Schneider: Chief Executive Officer 1 Disclaimer This presentation contains forward looking statements which reflect management s current

More information